CLINICAL_TRIALS
trial_result
· 2023-02-13
Clinical Trial Update: Rainbow Extension Study [Phase 3]
Summary
A Phase 3 extension study (Rainbow Extension Study) for retinopathy of prematurity has completed with results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Retinopathy of Prematurity (ROP) | Phase 3 | Status: COMPLETED | Results posted: 2023-02-13